Ureteroscopy Combined With Negative Pressure Sheath Treatment of Kidney Stones
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Apr 20, 2025
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 150/5000
- • 1. Patients diagnosed with kidney stones with a diameter of 2-3cm by CT;
- • 2. Age \> 18 years old;
- • 3. The anatomical structure of the kidney is normal, without deformity;
- • 4. Unilateral or bilateral kidney stones are not treated at the same time
- • 5. No serious heart and lung disease (ASA grade I-II)
- • 6. Through preoperative communication, patients and their family members indicated that they were fully aware of the condition and the choice of treatment plan, and signed informed consent and informed choice notification;
- Exclusion Criteria:
- • 1. Simultaneous operation is required for ipsilateral ureteral calculi or contralateral upper or lower urinary calculi.
- • 2. Severe coagulation dysfunction;
- • 3. Previous history of ipsilateral upper urinary tract surgery;
- • 4. Presence of urinary anatomic abnormalities or congenital malformations;
- • 5. Patients who do not sign informed consent and cannot cooperate with the study;
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported